抗原增强后HIV CAR T细胞在抗逆转录病毒治疗抑制的非人灵长类模型中强劲扩增
该研究在4只经抗逆转录病毒治疗(ART)抑制的猴/人免疫缺陷病毒(SHIV)感染恒河猴中,输注病毒特异性CD4CAR T细胞并补充细胞相关HIV-1包膜(Env)抗原。Env增强导致病毒特异性CAR+ T细胞在体内显著且前所未有的扩增;中断ART后,与对照组相比病毒反弹显著延迟(P = .014)。在2只CAR T细胞下降的动物中,使用抗PD-1抗体逆转免疫耗竭,触发耗竭CAR T细胞扩增并使病毒载量降至检测不到水平。
要点
- 在ART抑制的SHIV感染恒河猴中,补充细胞相关HIV-1 Env抗原使病毒特异性CAR+ T细胞在体内显著扩增。
- 中断ART后,Env增强组病毒反弹较对照组显著延迟(P = .014)。
- 抗PD-1抗体可逆转CAR T细胞耗竭,触发扩增并使病毒载量降至检测不到水平。
核心结论
- 补充细胞相关抗原可在抗原稀缺环境中实现CAR T细胞的强劲扩增。
- 据作者所知,这是首次在感染且病毒被抑制的宿主体内显示病毒特异性CAR T细胞扩增及病毒再激活的延迟/控制。
研究设计与样本
- 研究采用ART抑制的SHIV感染恒河猴模型,共4只恒河猴输注病毒特异性CD4CAR T细胞,随后补充输注细胞相关HIV-1包膜(Env)。
- 在2只CAR T细胞下降的动物中,给予恒河猴化抗程序性死亡蛋白1(PD-1)抗体以逆转PD-1依赖性免疫耗竭。
主要发现
- Env增强导致病毒特异性CAR+ T细胞在体内显著且前所未有的扩增。
- 中断ART后,Env增强组病毒反弹较对照组显著延迟(P = .014)。
- 在2只CAR T细胞下降的动物中,抗PD-1抗体触发耗竭CAR T细胞扩增,并使病毒载量降至检测不到水平。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells targeting CD19+ hematologic malignancies have rapidly emerged as a promising, novel therapy. In contrast, results from the few CAR T-cell studies for infectious diseases such as HIV-1 have been less convincing. These challenges are likely due to the low level of antigen present in antiretroviral therapy (ART)-suppressed patients in contrast to those with hematologic malignancies. Using our well-established nonhuman primate model of ART-suppressed HIV-1 infection, we tested strategies to overcome these limitations and challenges. We first optimized CAR T-cell production to maintain central memory subsets, consistent with current clinical paradigms. We hypothesized that additional exogenous antigen might be required in an ART-suppressed setting to aid expansion and persistence of CAR T cells. Thus, we studied 4 simian/HIV-infected, ART-suppressed rhesus macaques infused with virus-specific CD4CAR T cells, followed by supplemental infusion of cell-associated HIV-1 envelope (Env). Env boosting led to significant and unprecedented expansion of virus-specific CAR+ T cells in vivo; after ART treatment interruption, viral rebound was significantly delayed compared with controls (P = .014). In 2 animals with declining CAR T cells, rhesusized anti-programmed cell death protein 1 (PD-1) antibody was administered to reverse PD-1-dependent immune exhaustion. Immune checkpoint blockade triggered expansion of exhausted CAR T cells and concordantly lowered viral loads to undetectable levels. These results show that supplemental cell-associated antigen enables robust expansion of CAR T cells in an antigen-sparse environment. To our knowledge, this is the first study to show expansion of virus-specific CAR T cells in infected, suppressed hosts, and delay/control of viral recrudescence.
引用
- Rust BJ, Kean LS, Colonna L, et al. Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. Blood. 2020. PMID: 32614969. doi:10.1182/blood.2020006372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。